Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake epicrates cenchria crassus confrontation paradigm

Neuropsychopharmacology

Volumn 37, Issue 2, 2012, Pages 412-421

  Uribe Marĩo, Andrés ^a,b   Francisco, Audrey ^a   Castiblanco Urbina, Maria Angélica ^a,b   Twardowschy, André ^a   Salgado Rohner, Carlos José ^a   Crippa, José Alexandre S ^a,c   Hallak, Jaime Eduardo Cecílio ^a,c   Zuardi, Antnio Waldo ^a   Coimbra, Norberto Cysne ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute for Neuroscience and Behaviour (INeC)   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

cannabidiol; endocannabinoid mediated system; innate fear; panic related responses; prey vs predator paradigm

Indexed keywords

CANNABIDIOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFECATION; DEFENSIVE BEHAVIOR; DRUG EFFECT; EPICRATES CENCHRIA CRASSUS; ESCAPE BEHAVIOR; ETHOLOGY; FEAR; GROOMING; HABITUATION; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANIC; PREDATOR PREY INTERACTION; PRIORITY JOURNAL; REARING; RISK ASSESSMENT; SNAKE; THREAT;

ANIMALS; ANTI-ANXIETY AGENTS; CANNABIDIOL; DISEASE MODELS, ANIMAL; FEAR; HUMANS; INSTINCT; MALE; MICE; PANIC DISORDER; SNAKES;

EID: 84856053335     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.188     Document Type: Article

References (52)

1. Bisogno T, Hanus L, de Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852. (Pubitemid 33016156)
2. Blanchard DC, Blanchard RJ (1999). Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci Biobehav Rev 23: 981-991. (Pubitemid 29502403)
3. Blanchard DC, Griebel G, Blanchard RJ (2001). Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev 25: 205-218. (Pubitemid 32506874)
4. Blanchard DC, Griebel G, Blanchard RJ (2003). The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463: 97-116. (Pubitemid 36205074)
5. Blanchard DC, Griebel G, Rodgers RJ, Blanchard RJ (1998). Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. Neurosci Biobehav Rev 22: 597-612. (Pubitemid 28304900)
6. Borelli KG, Ferreira-Netto C, Coimbra NC, Brandão ML (2005). Fos-like immunoreactivity in the brain associated with freezing or escape induced by inhibition of either glutamic acid decarboxylase or GABAA receptors in the dorsal periaqueductal gray. Brain Res 1051: 100-111. (Pubitemid 40982631)
7. Borelli KG, Nobre MJ, Brandão ML, Coimbra NC (2004). Effects of acute and chronic fluoxetine and diazepam on freezing behavior induced by electrical stimulation of dorsolateral and lateral columns of the periaqueductal gray matter. Pharmacol Biochem Behav 77: 557-566. (Pubitemid 38296816)
8. Campos AC, Guimarães FS (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199: 223-230.
9. Canteras NS, Chiavegatto S, Valle LE, Swanson LW (1997). Severe reduction of rat defensive behavior to a predator by discrete hypothalamic chemical lesions. Brain Res Bull 44: 297-305. (Pubitemid 27413734)
10. Castellan-Baldan L, da Costa Kawasaki M, Ribeiro SJ, Calvo F, Corrêa VMA, Coimbra NC (2006). Topographic and functional neuroanatomical study of GABAergic disinhibitory striatumnigral inputs and inhibitory nigrocollicular pathways: neural hodology recruiting the substantia nigra, pars reticulata, for the modulation of the neural activity in the inferior colliculus involved with panic-like emotions. J Chem Neuroanat 32: 1-27. (Pubitemid 44234003)
11. Coimbra NC, Brandão ML (1993). GABAergic nigro-collicular pathways modulate the defensive behaviour elicited by midbrain tectum stimulation. Behav Brain Res 59: 131-139. (Pubitemid 24064878)
12. Coimbra NC, de Oliveira R, Freitas RL, Ribeiro SJ, Borelli KG, Pacagnella RC et al (2006). Neuroanatomical approaches of the tectum-reticular pathways and immunohistochemical evidence for serotonin-positive perikarya on neuronal substrates of the superior colliculus and periaqueductal gray matter involved in the elaboration of the defensive behavior and fear-induced analgesia. Exp Neurol 197: 93-112. (Pubitemid 41817224)
13. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L et al (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417-426. (Pubitemid 38175159)
14. Crippa JAS, Zuardi AW, Hallak JEC (2010). Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 32: 56-65.
15. 2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain Res Bull 64: 181-188.
16. Eichenberger GCD, Ribeiro SJ, Osaki MY, Maruoka RY, Resende GCC, Castellan-Baldan L et al (2002). Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter. Neuropharmacology 42: 48-59. (Pubitemid 34062821)
17. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA et al (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45: 594-604. (Pubitemid 36980816)
18. Freitas RL, Uribe-Mariño A, Castiblanco-Urbina MA, Elias-Filho DH, Coimbra NC (2009). GABAA receptor blockade in dorsomedial and ventromedial nuclei of the hypothalamus evokes paniclike elaborated defensive behaviour followed by innate fearinduced antinociception. Brain Res 1305: 118-131.
19. Fride E (2005). Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 4: 633-642. (Pubitemid 41782625)
20. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al (2009). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activ. Arch Gen Psychiatry 66: 95-105.
21. Graeff FG (1994). Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 27: 811-829.
22. Graeff FG, Brandão ML, Audi EA, Schutz MT (1986). Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav Brain Res 22: 173-180. (Pubitemid 17182276)
23. Graham ES, Ashton JC, Glass M (2009). Cannabinoid receptors: a brief history and 'what's hot'. Front Biosci 14: 944-957.
24. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000). Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493-505. (Pubitemid 30191187)
25. Guimarães FS, Chiaretti TM, Graeff F, Zuardi AW (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100: 558-559. (Pubitemid 20102368)
26. Guimarães-Costa R, Guimarães-Costa MB, Pippa-Gadioli L, Weltson A, Ubiali WA, Paschoalin-Maurin T et al (2007). Innate defensive behavior and panic-like reactions evoked by rodents during aggressive encounters with Brazilian constrictor snakes in a complex labyrinth: behavioural validation of a new model to study affective and agonistic reactions in a prey vs predator paradigm. J Neurosci Meth 165: 25-37. (Pubitemid 47077495)
27. Griebel G, Blanchard DC, Blanchard RJ (1996). Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attacks. Prog Neuro-Psychopharmacol Biol Psychiatry 20: 185-205. (Pubitemid 26153184)
28. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
29. Kellner M, Muhtz C, Demiralay C, Husemann J, Koelsch W, Yassouridis A et al (2009). The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. J Psychiatry Res 43: 642-648.
30. Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS (2008). Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593: 73-78.
31. Lobão-Soares B, Walz R, Schroder Prediger RD, Freitas RL, Calvo F, Bianchin MM et al (2008). Cellular prion protein modulates defensive attention and innate fear-induced behaviour evoked in transgenic mice submitted to an agonistic encounter with the tropical coral snake Oxyrhopus guibei. Behav Brain Res 194: 129-137.
32. Mackowiak M, Chocyk A, Dudys D, Wedzony K (2009). Activation of CB1 cannabinoid receptors impairs memory consolidation and hippocampal polysialylated neural cell adhesion molecule expression in contextual fear conditioning. Neurosci 158: 1708-1716.
33. Marco EM, Viveros MP (2009). Functional role of the endocannabinoid system in emotional homeostasis. Rev Neurol 48: 20-26.
34. Mikics E, Vas J, Aliczki M, Halasz J, Haller J (2009). Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 20: 265-272.
35. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al (2005). Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36: 1077-1082.
36. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B et al (2007). When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 314: 1079-1083. (Pubitemid 47330191)
37. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB et al (2009a). Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plast 625-469.
38. Moreira FA, Grieb M, Lutz B (2009b). Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23: 133-144.
39. Motta SC, Goto M, Gouveia FV, Baldo MV, Canteras NS, Swanson LW (2009). Dissecting the brain's fear system reveals the hypothalamus is critical for responding in subordinate conspecific intruders. Proc Natl Acad Sci USA 106: 4870-4875.
40. Onaivi ES, Ishiguro H, Gong J-J, Patel S, Perchuk A, Meozzi PA et al (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in Brain. Proc Natl Acad Sci USA 1074: 514-536. (Pubitemid 44532857)
41. Pollack MH, Marzol PC (2000). Panic: course, complications and treatment of panic disorder. J Psychopharmacol 14(Suppl 1): S25-S30. (Pubitemid 30389498)
42. Resstel LB, Lisboa SF, Aguiar DC, Correa FM, Guimarães FS (2008). Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology (Berl) 198: 405-411.
43. Resstel LB, Tavares RF, Lisboa SF, Joça SR, Correa FM, Guimarães FS (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
44. Ribeiro SJ, Ciscato Jr JG, De Oliveira R, de Oliveira RC, d'Â ngelo-Dias R, Carvalho AD et al (2005). Functional and ultrastructural neuroanatomy of interactive intratectal/tectonigral mesencephalic opioid inhibitory links and nigrotectal GABAergic pathways: involvement of GABAA and m1-opioid receptors in the modulation of panic-like reactions elicited by electrical stimulation of the dorsal midbrain. J Chem Neuroanat 30: 184-200. (Pubitemid 41579110)
45. Roser P, Vollenweider FX, Kawohl W (2008). Potential antipsychotic properties of central cannabinoid CB1 receptor antagonists. World J Biol Psychiatry 1-12.
46. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
47. Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME et al (2009). Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 15: 19-23.
48. Thiemann G, Watt CA, Ledent C, Molleman A, Hasenohrl RU (2009). Modulation of anxiety by acute blockade and genetic deletion of the CB1 cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 200: 60-67.
49. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623. (Pubitemid 46355558)
50. Zarrindast MR, Sarahroodi S, Arzi A, Khodayar MJ, Taheri-Shalmani S, Rezayof A (2008). Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav Pharmacol 19: 716-723.
51. Zuardi AW, Cosme RA, Graeff FG (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88. (Pubitemid 23099702)
52. Zuardi AW (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.